KR102472774B1 - 안과용 약학 조성물 및 이와 관련된 용도 - Google Patents

안과용 약학 조성물 및 이와 관련된 용도 Download PDF

Info

Publication number
KR102472774B1
KR102472774B1 KR1020197007252A KR20197007252A KR102472774B1 KR 102472774 B1 KR102472774 B1 KR 102472774B1 KR 1020197007252 A KR1020197007252 A KR 1020197007252A KR 20197007252 A KR20197007252 A KR 20197007252A KR 102472774 B1 KR102472774 B1 KR 102472774B1
Authority
KR
South Korea
Prior art keywords
delete delete
pharmaceutical composition
concentration
ophthalmic pharmaceutical
pilocarpine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197007252A
Other languages
English (en)
Korean (ko)
Other versions
KR20190051973A (ko
Inventor
클래스 페인바움
프랑 살라문
수디르 파텔
Original Assignee
오라시스 파마슈티칼스 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60935566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102472774(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 오라시스 파마슈티칼스 엘티디. filed Critical 오라시스 파마슈티칼스 엘티디.
Priority to KR1020227041350A priority Critical patent/KR102588499B1/ko
Publication of KR20190051973A publication Critical patent/KR20190051973A/ko
Application granted granted Critical
Publication of KR102472774B1 publication Critical patent/KR102472774B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020197007252A 2016-08-19 2017-08-18 안과용 약학 조성물 및 이와 관련된 용도 Active KR102472774B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227041350A KR102588499B1 (ko) 2016-08-19 2017-08-18 안과용 약학 조성물 및 이와 관련된 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662377154P 2016-08-19 2016-08-19
US62/377,154 2016-08-19
PCT/IB2017/001140 WO2018033792A2 (en) 2016-08-19 2017-08-18 Ophthalmic pharmaceutical compositions and uses relating thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227041350A Division KR102588499B1 (ko) 2016-08-19 2017-08-18 안과용 약학 조성물 및 이와 관련된 용도

Publications (2)

Publication Number Publication Date
KR20190051973A KR20190051973A (ko) 2019-05-15
KR102472774B1 true KR102472774B1 (ko) 2022-11-30

Family

ID=60935566

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197007252A Active KR102472774B1 (ko) 2016-08-19 2017-08-18 안과용 약학 조성물 및 이와 관련된 용도
KR1020227041350A Active KR102588499B1 (ko) 2016-08-19 2017-08-18 안과용 약학 조성물 및 이와 관련된 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227041350A Active KR102588499B1 (ko) 2016-08-19 2017-08-18 안과용 약학 조성물 및 이와 관련된 용도

Country Status (13)

Country Link
US (6) US9867810B1 (cg-RX-API-DMAC7.html)
EP (2) EP4190328A1 (cg-RX-API-DMAC7.html)
JP (3) JP7297308B2 (cg-RX-API-DMAC7.html)
KR (2) KR102472774B1 (cg-RX-API-DMAC7.html)
CN (2) CN116726006A (cg-RX-API-DMAC7.html)
AU (2) AU2017311636B2 (cg-RX-API-DMAC7.html)
CA (1) CA3031370A1 (cg-RX-API-DMAC7.html)
ES (1) ES2934790T3 (cg-RX-API-DMAC7.html)
IL (2) IL264664B2 (cg-RX-API-DMAC7.html)
MX (2) MX2019001877A (cg-RX-API-DMAC7.html)
PL (1) PL3500255T3 (cg-RX-API-DMAC7.html)
PT (1) PT3500255T (cg-RX-API-DMAC7.html)
WO (1) WO2018033792A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
KR102472774B1 (ko) * 2016-08-19 2022-11-30 오라시스 파마슈티칼스 엘티디. 안과용 약학 조성물 및 이와 관련된 용도
JP6946575B2 (ja) 2018-04-24 2021-10-06 アラーガン、インコーポレイテッドAllergan,Incorporated 眼の状態の治療のためのピロカルピン塩酸塩の使用
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
JP2022508715A (ja) 2018-10-15 2022-01-19 オキュフィア・ファーマ・インコーポレイテッド 緑内障および関連状態の処置のための方法および組成物
DK3870170T3 (da) 2018-10-26 2026-05-26 Opus Genetics Inc Behandling af presbyopi og mydriasis med fentolamin
EP3965732A4 (en) * 2019-05-08 2023-06-14 Harrow IP, LLC PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA AND PROCESS FOR THEIR PREPARATION
BR112022026911A2 (pt) * 2020-09-11 2023-03-28 Intratus Nevada Inc Composições e métodos para tratar presbiopia, hipermetropia, astigmatismo, diminuição da estereopsia e diminuição da sensibilidade ao contraste
MX394625B (es) * 2020-11-12 2025-03-24 Cesar Alejandro Sanchez Galeana Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia
US20240139166A1 (en) * 2021-02-04 2024-05-02 Sydnexis, Inc. Ophthalmic compositions for presbyopia
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
WO2023052977A1 (en) * 2021-09-29 2023-04-06 Avaca Pharma Private Limited Compositions, methods and uses thereof
US20230263727A1 (en) * 2022-01-14 2023-08-24 Somerset Therapeutics, Llc Ophthalmologically suitable low pka buffer-containing pilocarpine compositions and related methods
US20250154135A1 (en) * 2022-01-29 2025-05-15 Nanjing Gritpharma Co., Ltd. M-choline receptor agonist compound, preparation method therefor and use thereof
US11969410B2 (en) 2022-02-09 2024-04-30 Somerset Therapeutics, Llc Low pH pilocarpine and brimonidine compound formulations and related methods
CN119700989A (zh) 2023-09-28 2025-03-28 苏州普乐康医药科技有限公司 一种α-肾上腺素受体激动剂眼用组合物及其用途
CN117414333A (zh) * 2023-11-30 2024-01-19 南京正科医药股份有限公司 盐酸毛果芸香碱滴眼液及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008074865A1 (en) 2006-12-21 2008-06-26 Novo Nordisk A/S Dimeric prolactin receptor ligands
WO2015122853A1 (en) * 2014-02-11 2015-08-20 Vid D.O.O. Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255415A (en) * 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
IT1229075B (it) 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2064160C (en) 1991-03-27 1998-08-11 Paul J. T. Missel Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
SE9401109D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Opthalmic composition II
SE9401108D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
US6309630B1 (en) * 1994-05-24 2001-10-30 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic suspensions
US5698533A (en) 1994-07-26 1997-12-16 Kang; Meng-Che Ophthalmic pharmaceutical composition
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US5612027A (en) 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
TW389694B (en) 1995-08-17 2000-05-11 Novartis Ag Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics
CA2193149C (en) * 1995-12-22 2002-04-23 David H. Donabedian Cationic therapuetic agents and delivery systems
AU2287597A (en) 1996-03-13 1997-10-01 Laboratoires Merck Sharp & Dohme - Chibret Snc Ophthalmological composition of the type which undergoes liquid-gel phase tr ansition
EP0995435B1 (en) 1997-05-14 2007-04-25 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility
US6265444B1 (en) 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
SE0002211D0 (sv) 2000-06-13 2000-06-13 Synphora Ab Methods and compositions for prevention of myopia
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
EP1299123A2 (en) 2000-07-13 2003-04-09 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
US6540990B2 (en) 2000-09-22 2003-04-01 Gerard M. Nolan Physiological method of improving vision
US6605640B2 (en) 2001-01-31 2003-08-12 Gerard M. Nolan Method of treating certain eye diseases
US6273092B1 (en) 2000-09-22 2001-08-14 Gerard M. Nolan Methods for treating various eye disorders
US20020160988A1 (en) 2001-02-20 2002-10-31 Israel Institute For Biological Research Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
US20040058926A1 (en) 2001-05-04 2004-03-25 Rebanta Bandyopadhyay Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
AR034371A1 (es) 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
US20030018382A1 (en) 2001-07-17 2003-01-23 Pflugfelder Stephen C. Process for improving vision
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US20050208102A1 (en) 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
CA2839849C (en) 2003-06-13 2017-03-07 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
EP1654002B2 (en) * 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050119262A1 (en) 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
EP1611879B1 (en) 2004-07-02 2009-08-12 Novagali Pharma SA Use of emulsions for intra- and periocular injection
WO2006062875A1 (en) 2004-12-08 2006-06-15 Merck & Co., Inc. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
WO2008011836A2 (es) 2006-07-25 2008-01-31 Osmotica Corp. Soluciones oftálmicas
ATE439863T1 (de) 2006-12-18 2009-09-15 Jorge Luis Benozzi Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie
WO2008094659A2 (en) 2007-01-31 2008-08-07 Allergan, Inc. Novel biomaterials for ocular drug delivery and a method for making and using same
WO2008130591A2 (en) 2007-04-18 2008-10-30 The Gi Company, Inc. Using trefoil polypeptides to treat eye lesions associated with ophthalmic procedures
CN101754748A (zh) 2007-05-24 2010-06-23 阿西克斯医疗公司 治疗干眼症的制剂和方法
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
US20100298335A1 (en) 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2011079123A1 (en) 2009-12-23 2011-06-30 Alimera Sciences, Inc. Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids
IN2014CN02961A (cg-RX-API-DMAC7.html) 2011-09-20 2015-07-03 Altavista Inst De Invest Medica S A S
US10507245B2 (en) * 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
US10064818B2 (en) * 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
ES2538551B1 (es) * 2013-12-20 2016-01-13 Eurocanarias Oftalmológica, Sl Composición Oftálmica para la corrección de la presbicia
KR102472774B1 (ko) * 2016-08-19 2022-11-30 오라시스 파마슈티칼스 엘티디. 안과용 약학 조성물 및 이와 관련된 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008074865A1 (en) 2006-12-21 2008-06-26 Novo Nordisk A/S Dimeric prolactin receptor ligands
WO2015122853A1 (en) * 2014-02-11 2015-08-20 Vid D.O.O. Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration

Also Published As

Publication number Publication date
IL264664B (en) 2022-11-01
CN109803652A (zh) 2019-05-24
JP2019524826A (ja) 2019-09-05
JP2025168426A (ja) 2025-11-07
EP3500255B1 (en) 2022-11-30
PT3500255T (pt) 2023-01-10
CA3031370A1 (en) 2018-02-22
IL264664A (cg-RX-API-DMAC7.html) 2019-03-31
IL264664B2 (en) 2023-03-01
JP7839560B2 (ja) 2026-04-02
MX2019001877A (es) 2019-09-13
US10639297B2 (en) 2020-05-05
ES2934790T3 (es) 2023-02-27
KR20220162876A (ko) 2022-12-08
RU2019107585A (ru) 2020-09-21
BR112019002967A2 (pt) 2019-05-14
EP3500255A4 (en) 2020-03-25
US20200222369A1 (en) 2020-07-16
US11129812B2 (en) 2021-09-28
WO2018033792A2 (en) 2018-02-22
EP4190328A1 (en) 2023-06-07
RU2019107585A3 (cg-RX-API-DMAC7.html) 2020-12-22
WO2018033792A3 (en) 2018-03-29
PL3500255T3 (pl) 2023-03-13
US20180207136A1 (en) 2018-07-26
US20220184039A1 (en) 2022-06-16
CN116726006A (zh) 2023-09-12
AU2017311636B2 (en) 2023-08-10
AU2023226732A1 (en) 2023-09-28
IL297367A (en) 2022-12-01
US11974986B2 (en) 2024-05-07
JP7297308B2 (ja) 2023-06-26
KR102588499B1 (ko) 2023-10-11
US20250268867A1 (en) 2025-08-28
JP2023105147A (ja) 2023-07-28
US9867810B1 (en) 2018-01-16
MX2023003124A (es) 2023-03-22
KR20190051973A (ko) 2019-05-15
AU2017311636A1 (en) 2019-02-14
US20180318264A1 (en) 2018-11-08
EP3500255A2 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
JP7839560B2 (ja) 眼科用医薬組成物及びそれに関する使用
KR20210005134A (ko) 안구 증상의 치료를 위한 필로카르핀 염산염의 용도
JP2020055851A (ja) 老視を治療するための組成物及び方法
US7915312B2 (en) Physiological method of improving vision
Lee et al. Measurement of contrast sensitivity and glare under mesopic and photopic conditions following wavefront-guided and conventional LASIK surgery
Goss et al. Optometric clinical practice guideline care of the patient with myopia
KR20230042077A (ko) 노안, 원시, 난시, 감소된 입체시, 및 감소된 대비 감도를 치료하기 위한 조성물 및 방법
Orman et al. Overview of pharmacological treatments for presbyopia
RU2791371C2 (ru) Офтальмологические фармацевтические композиции и их применение
HK40094546A (en) Ophthalmic pharmaceutical compositions and uses relating thereto
HK40002937A (en) Ophthalmic pharmaceutical compositions and uses relating thereto
HK40002937B (en) Ophthalmic pharmaceutical compositions and uses relating thereto
BR112019002967B1 (pt) Composição farmacêutica oftálmica, uso de uma composição farmacêutica oftálmica, implante, e, kit
Pepose Treatment of Presbyopia: One of Several Potential Indications for Nyxol

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

V11 Administrative appeal requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-V10-V11-APL-PJ0204 (AS PROVIDED BY THE NATIONAL OFFICE)